World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
33812
World Ranking
15409
National Ranking
7772

Paul J. Catalano publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paul J. Catalano sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 367 publications — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paul J. Catalano D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paul J. Catalano sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paul J. Catalano is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a strong emphasis on oncology and related subfields. Their publication record includes a significant number of works focused on pulmonary and respiratory medicine, oncology, genetics, cancer research, and radiology, nuclear medicine, and imaging.

The subfields covered by their research include:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Genetics
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging

The research topics Paul J. Catalano has worked on cover various critical areas in medical oncology:

  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Renal Cell Carcinoma Treatment
  • Cancer Immunotherapy and Biomarkers
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics

Among recent papers authored or coauthored by Catalano are:

  • Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (2022, Journal of Clinical Oncology)
  • Large language models to identify social determinants of health in electronic health records (2024, npj Digital Medicine)
  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 (2023, Journal of Clinical Oncology)
  • KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1 (2020, Cancer Immunology Research)
  • Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma (2020, Clinical Cancer Research)

Frequent coauthors include:

  • Daphne A. Haas-Kogan (35 collaborative papers)
  • Ayal A. Aizer (32 collaborative papers)
  • Daniel Cagney (23 collaborative papers)
  • Nayan Lamba (22 collaborative papers)
  • Patrick Y. Wen (20 collaborative papers)

The primary publication venues where Catalano's research appears most often encompass:

  • Journal of Clinical Oncology (29 publications)
  • International Journal of Radiation Oncology*Biology*Physics (15 publications)
  • Neuro-Oncology (11 publications)
  • Journal for ImmunoTherapy of Cancer (4 publications)
  • JNCI Journal of the National Cancer Institute (4 publications)

Paul J. Catalano's research contributions predominantly focus on clinical and translational aspects of cancer treatment, diagnosis, and biomarker identification, drawing upon interdisciplinary approaches across multiple oncology subfields. Their collaboration network and publication venues reflect sustained involvement in high-impact clinical oncology research.

Best Publications

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089

    T.E. Le Voyer;E.R. Sigurdson;A.L. Hanlon;R.J. Mayer

  • Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer

    Jane C. Weeks;Paul J. Catalano;Angel Cronin;Matthew D. Finkelman

  • Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

    Toshiaki Watanabe;Tsung Teh Wu;Paul J. Catalano;Paul J. Catalano;Takashi Ueki

  • Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

    Jordan D. Berlin;Paul Catalano;James P. Thomas;John W. Kugler

  • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

    David A. Braun;David A. Braun;Yue Hou;Ziad Bakouny;Miriam Ficial;Miriam Ficial

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Under-reporting of alcohol consumption in household surveys: a comparison of quantity-frequency, graduated-frequency and recent recall.

    Tim Stockwell;Susan Donath;Mark Cooper-Stanbury;Tanya Chikritzhs

  • Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

    Daniel N Cagney;Allison M Martin;Paul J Catalano;Amanda J Redig

  • Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes

    Adam C. Berger;Elin R. Sigurdson;Thomas LeVoyer;Alexandra Hanlon

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer.

    Daniel N. Cagney;Allison M. Martin;Paul J. Catalano;Paul D. Brown

  • Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089

    Daniel G. Haller;Paul J. Catalano;John S. Macdonald;Mark A. O'Rourke

  • Impact of diabetes mellitus on outcomes in patients with colon cancer.

    Jeffrey A. Meyerhardt;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

  • Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281

    Weijing Sun;Stuart Lipsitz;Paul Catalano;James A. Mailliard

  • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

    B. J. Giantonio;P. J. Catalano;N. J. Meropol;P. J. O'Dwyer

  • Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

    C R Nichols;P J Catalano;E D Crawford;N J Vogelzang

  • Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

    Jeffrey A. Meyerhardt;Paul J. Catalano;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

  • Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

    Malcolm A. Smith;Lawrence Rubinstein;James R. Anderson;Diane Arthur

  • Impact o f D iabetes M ellitus o n O utcomes i n P atients W ith Colon C ancer

    Jeffrey A. Meyerhardt;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

Frequent Co-Authors

Al B. Benson
Al B. Benson Northwestern University
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Brian M. Alexander
Brian M. Alexander Foundation Medicine
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
Peter J. O'Dwyer
Peter J. O'Dwyer University of Pennsylvania
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Robert I. Haddad
Robert I. Haddad Harvard University
Petros Koutrakis
Petros Koutrakis Harvard University
Tanya Chikritzhs
Tanya Chikritzhs Curtin University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a traditional route. There are many flexible online degree options that allow students to enter or advance within the healthcare field. For instance, bsn to np programs online offer registered nurses the opportunity to become nurse practitioners with a psychiatric mental health focus, entirely from home. This flexibility is ideal for working professionals.

Want to focus on healthcare management? Choosing an affordable healthcare administration degree online or exploring affordable mha online programs can open doors to leadership roles in hospitals, clinics, and organizations, without the high cost of traditional education.

Those looking for the highest clinical expertise may consider cheap online dnp programs, which prepare nurses for advanced practice and leadership roles. These alternative pathways allow students to balance education and life while moving toward impactful roles in healthcare—proving you can achieve your career goals without being limited by geography or high tuition.

Best Scientists Citing Paul J. Catalano

Trending Scientists